Free Trial
OTCMKTS:SPHDF

Santhera Pharmaceuticals (SPHDF) Stock Price, News & Analysis

Santhera Pharmaceuticals logo
$11.70 0.00 (0.00%)
(As of 11/20/2024 ET)

About Santhera Pharmaceuticals Stock (OTCMKTS:SPHDF)

Key Stats

Today's Range
$11.70
$11.70
50-Day Range
$11.70
$11.70
52-Week Range
$9.40
$13.35
Volume
N/A
Average Volume
400 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes Vamorolone, which is being developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.

Santhera Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
2nd Percentile Overall Score

SPHDF MarketRank™: 

Santhera Pharmaceuticals scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Santhera Pharmaceuticals.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Santhera Pharmaceuticals is -8.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Santhera Pharmaceuticals is -8.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

  • Short Interest Ratio / Days to Cover

    Santhera Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

  • Dividend Yield

    Santhera Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Santhera Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

  • Short Interest Ratio / Days to Cover

    Santhera Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

  • News Sentiment

    Santhera Pharmaceuticals has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.
Receive SPHDF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Santhera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SPHDF Stock News Headlines

[625,000% Gain] – Are You Ready for the Next Altcoin Boom?
All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.
Santhera Pharmaceuticals Holding (SANN)
Santhera Pharma H1 Net Loss Narrows, Revenues Climb
See More Headlines

SPHDF Stock Analysis - Frequently Asked Questions

Santhera Pharmaceuticals' stock was trading at $11.70 at the beginning of the year. Since then, SPHDF stock has increased by 0.0% and is now trading at $11.70.
View the best growth stocks for 2024 here
.

Santhera Pharmaceuticals's stock reverse split on Monday, July 3rd 2023. The 1-10 reverse split was announced on Monday, July 3rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of SPHDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:SPHDF
CIK
N/A
Fax
N/A
Employees
45
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

This page (OTCMKTS:SPHDF) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners